Adverse Event Label Expansion for GLP-1 Medications Due toOff-Label Use: Regulatory Implications and Challenges
DOI:
https://doi.org/10.14419/n99q9v48Published
19-05-2026Keywords:
GLP-1 Receptor Agonists; Off-Label Drug Use; Adverse Event Label Expansion; Pharmacovigilance; Regulatory HarmonizationAbstract
The high-velocity growth of off-label administration of glucagon-like peptide-1 (GLP-1) receptor agonists that were initially approved to be used as Type 2 diabetes medications has raised new safety issues and initiated regulatory procedures for developing adverse event label expansions. Since these agents are becoming popular in weight reduction, the treated population has become less homogenous, and therefore, the risk of adverse events that were not seen during the pre-approval trials is more probable. The paper critically evaluates the pharmacological justification of off-label use, the role of post-marketing surveillance in identifying safety signals, and the regulatory frameworks of various jurisdictions regarding the correction of the labeling of that product. It also deals with regulatory communication obligations of regulators, manufacturers, and prescribers to communicate changing risks; and with operational impediments to the successful implementation of label changes in a timely and consistent manner. It outlines the evidential challenges in demonstrating causality among various patient groups as well as recommending approaches to future regulation, including the development of dynamic labeling systems, streamlined global pharmacovigilance, and enhanced safety research. Analysis indicates that the adaptive, coordinated, and evidence-based strategies are essential to ensure the protection of public health and, at the same time, maintain access to therapeutics in the new reality of changing prescription patterns at a blistering pace.
References
Liu, Q. K. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology, 15, 1431292. https://doi.org/10.3389/fendo.2024.1431292.
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. (2013). A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 thera-pies safe? Diabetes Care, 36(7), 2118-2125. https://doi.org/10.2337/dc12-2713.
Alenzi, K. A., Alsuhaibani, D., Batarfi, B., & Alshammari, T. M. (2024). Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology, 15, 1364110. https://doi.org/10.3389/fphar.2024.1364110.
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024). Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. The Lancet Gastroenterology & Hepatology, 9(10), 957-964. https://doi.org/10.1016/S2468-1253(24)00188-2.
Jarow, J. P., & Moscicki, R. (2017). Impact of expanded access on FDA regulatory action and product labeling. Therapeutic Innovation & Regulatory Science, 51(6), 787-789. https://doi.org/10.1177/2168479017707800.
Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., ... & Gong, F. (2022). The anti-obesity effect and safety of GLP-1 receptor agonist in over-weight/obese patients without diabetes: a systematic review and meta-analysis. Hormone and Metabolic Research, 54(07), 458-471. https://doi.org/10.1055/a-1844-1176.
Li, Y., Wu, Y., Jiang, T., Xing, H., Xu, J., Li, C., ... & Liu, Y. (2023). Opportunities and challenges of pharmacovigilance in special populations: a nar-rative review of the literature. Therapeutic Advances in Drug Safety, 14, 20420986231200746. https://doi.org/10.1177/20420986231200746.
Gupta, S. K., & Nayak, R. P. (2014). Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies, and regulatory authori-ties. Journal of Pharmacology and Pharmacotherapeutics, 5(2), 88-92. https://doi.org/10.4103/0976-500X.130046.
Bessesen, D. H., & Van Gaal, L. F. (2018). Progress and challenges in anti-obesity pharmacotherapy. The Lancet Diabetes & Endocrinology, 6(3), 237-248. https://doi.org/10.1016/S2213-8587(17)30236-X.
Hayes, M. R., Borner, T., & De Jonghe, B. C. (2021). The role of GIP in the regulation of GLP-1 satiety and nausea. Diabetes, 70(9), 1956-1961. https://doi.org/10.2337/dbi21-0004.
Hankir, M. K., & Lutz, T. A. (2025). Novel neural pathways targeted by GLP-1R agonists and bariatric surgery. Pflügers Archiv-European Journal of Physiology, 477(2), 171-185. https://doi.org/10.1007/s00424-024-03047-3.
Ryan, D., & Acosta, A. (2015). GLP‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity, 23(6), 1119-1129. https://doi.org/10.1002/oby.21107.
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., ... & Cosentino, F. (2018). GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1864(9), 2814-2821. https://doi.org/10.1016/j.bbadis.2018.05.012.
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., ... & Madej, P. (2022). The role of GLP-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. International Journal of Molecular Sciences, 23(8), 4334. https://doi.org/10.3390/ijms23084334.
Onoviran, O. F., Li, D., Toombs Smith, S., & Raji, M. A. (2019). Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older pa-tients with diabetes mellitus. Therapeutic Advances in Chronic Disease, 10, 2040622319862691. https://doi.org/10.1177/2040622319862691.
Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2012). Incretin‐based therapies. Journal of Diabetes, 4(1), 55-67. https://doi.org/10.1111/j.1753-0407.2011.00143.x.
He, L., Li, J., Cheng, X., Luo, L., & Huang, Y. (2025). Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigi-lance analysis. Frontiers in Pharmacology, 16, 1509561. https://doi.org/10.3389/fphar.2025.1509561.
Chen, W., Cai, P., Zou, W., & Fu, Z. (2024). Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Frontiers in Endocrinology, 15, 1330936. https://doi.org/10.3389/fendo.2024.1330936.
He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang,Y., & Zhong, X. (2024). Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutri-tional adverse events. Frontiers in Pharmacology, 15, 1416985. https://doi.org/10.3389/fphar.2024.1416985.
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H., Peters, T. M., & Eisenberg, M. J. (2025). The expanding role of GLP-1 receptor agonists: a narra-tive review of current evidence and future directions. EClinicalMedicine, 86. https://doi.org/10.1016/j.eclinm.2025.103363.
Fusaroli, M., Salvo, F., Begaud, B., AlShammari, T. M., Bate, A., Battini, V., ... & Khouri, C. (2024). The Reporting of A disproportionality analysis for Drug safety signal detection using individual case safety reports in Pharmacovigilance (READUS-PV): explanation and elaboration. Drug Safety, 47(6), 585-599. https://doi.org/10.1007/s40264-024-01423-7.
Gravel, C. A., & Douros, A. (2023). Considerations on the use of different comparators in pharmacovigilance: a methodological review. British Jour-nal of Clinical Pharmacology, 89(9), 2671-2676. https://doi.org/10.1111/bcp.15802.
Agbabiaka, T. B., Savović, J., & Ernst, E. (2008). Methods for causality assessment of adverse drug reactions: a systematic review. Drug Safety, 31(1), 21-37. https://doi.org/10.2165/00002018-200831010-00003.
Pore, A. V., Bais, S. K., & Kamble, M. M. (2024). Pharmacovigilance in clinical research. International Journal of Pharmacy and Herbal Technolo-gy, 2(1), 759-775.
Olsson, S. (1998). The role of the WHO program on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Safety, 19(1), 1-10. https://doi.org/10.2165/00002018-199819010-00001.
Thomson, R., Edwards, A., & Grey, J. (2005). Risk communication in the clinical consultation. Clinical Medicine, 5(5), 465-469. https://doi.org/10.7861/clinmedicine.5-5-465.
Dellgren, J. L., Persad, G., & Emanuel, E. J. (2024). International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches. The Lancet. https://doi.org/10.1016/S0140-6736(24)01356-4.
Singh, A., Twomey, K., & Baker, R. (2018). Global pharmacovigilance regulations: call for re-harmonization. Clinical Trials, 15(6), 631-632. https://doi.org/10.1177/1740774518801592.
Garg, S. K., Snell-Bergeon, J., Kaur, G., & Beatson, C. (2024). Challenges of GLP analog use for people with type 1 diabetes: Issues with prior ap-provals and tips for safer use. Diabetes Technology & Therapeutics, 26(6), 363-366. https://doi.org/10.1089/dia.2024.0023.
Davis, T. C., Federman, A. D., Bass III, P. F., Jackson, R. H., Middlebrooks, M., Parker, R. M., & Wolf, M. S. (2009). Improving patient understand-ing of prescription drug label instructions. Journal of General Internal Medicine, 24(1), 57-62. https://doi.org/10.1007/s11606-008-0833-4.